A BENZIMIDAZOLE DERIVATIVE AS AN EFFECTIVE ANTITUMOR AGENT IN TERMS OF SYNGENEIC LUNG TUMORS AND MELANOMA TREATMENT

E. F. Komarova1,2, A. S. Morkovnik3, O. N. Zhukovskaya2, E. V. Verenikina1, N. A. Shevchenko1, D. V. Khodakova1, L. Z. Kurbanova1, M. V. Mindar1, E. V. Zaikina1, A. V. Galina1

1. National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation
2. Rostov State Medical University, Rostov-on-don, Russian Federation
3. Institute of Physical and Organic Chemistry at Southern Federal University, Rostov-on-don, Russian Federation
katitako@gmail.com

ABSTRACT

Purpose of the study. Evaluation of the effect of the benzimidazole derivative dihydrobromide-2-(3,4-dihydroxyphenyl)-9-diethylamino-ethylimidazo-[1,2-α] benzimidazole (RU-185) on the growth of Lewis lung epidermoid carcinoma and B16-F10 melanoma when administered intragastrically.

Materials and methods. For the experiment, we used female C57Bl/6j mice, which were inoculated subcutaneously with syngeneic tumors: Lewis lung carcinoma (LLC) and B16-F10 melanoma. RU-185 was administered intragastrically to animals in a volume of 0.3 ml for 10 days, 1 time per day. For both tumors, depending on single doses of the substance for administration, groups were divided: 1st and 4th – 50 mg/kg, 2nd and 5th – 220 and 3rd and 6th – 500 mg/kg. The control groups were injected intragastrically with physiological saline in the same volumes and according to the same scheme. The following parameters were assessed: tumor volume, increase in life expectancy (T/S, %) and tumor growth inhibition index (TGI, %).

Results. For animals with LLC in the 2nd group there is an increase in the indicator of life expectancy (T/S 162.3 %), and in the 3rd group there is a tendency to an increase in the T/S indicator. On the 1st day after the end of treatment in the 2nd and 3rd groups TGI was 73.0 % and 30.1 %, respectively (p < 0.05). On the 7th and 14th days after the end of the use of RU-185 in the 2nd and 3rd groups the volume of tumors is 3.5 and 1.4 times less (on the 7th day) and 2.3 and 1.3 times (on the 14th day), respectively than in the control group (p < 0.05). At a dose of 220 mg/kg, complete regression of LLC tumors was shown in 20 % of animals.

With the growth of B16-F10, the life expectancy of all groups did not differ. Intergroup differences in the dynamics of tumor growth are provided. Highlighted changes were found in the 5th group (on the 14th day after the end of the administration of RU-185, TGI was 48.7 %).

Conclusion. The investigated chemical substance dihydrobromide-2-(3,4-dihydroxyphenyl)-9-diethylamino-ethylimidazo-[1,2-α] benzimidazole showed antitumor efficacy against syngeneic tumors: Lewis lung epidermoid carcinoma and B16-F10 melanoma when administered intragastrically which leads to further testing of RU-185 as a potential drug for the treatment of malignant neoplasms.

Keywords:
dihydrobromide-2-(3,4-dihydroxyphenyl)-9-diethylamino-ethylimidazo-[1,2-α] benzimidazole, Lewis lung carcinoma, melanoma B16-F10, antitumor efficacy, intragastric administration
Цель исследования. Оценка влияния производного бензимидазола дигидробромид-2-(3,4-дигидроксифенил)-9-диэтиламиноэтимидазо-[1,2-a] бензимидазола (РУ-185) на рост эпидермоидной карциномы легкого Льюиса и меланомы B16-F10 при внутрижелудочном применении.

Материалы и методы. Для эксперимента использовали мышей линии C57Bl/6j самок, которым подкожно прививали сингенные опухоли: эпидермоидная карцинома легких Льюис (LLC) и меланома B16-F10. РУ-185 вводили внутрижелудочно животным в объеме 0,3 мл в течение 10 дней 1 раз всутки. Для обеих опухолей в зависимости от разовых доз субстанции для введения выделены группы: 1-я и 4-я – 50 мг/кг, 2-я и 5-я – 220 и 3-я и 6-я – 500 мг/кг. Контрольным группам внутрижелудочно вводили физиологический раствор в аналогичных объемах и по той же схеме. Оценивали показатели: объем опухоли, увеличение продолжительности жизни (Т/С, %) и индекс торможения роста опухоли (ТРО, %).

Результаты. Для животных с LLC во 2-й группе отмечается увеличение показателя продолжительности жизни (Т/С 162,3 %), а в 3-й показана тенденция к повышению показателя Т/С. В 1-е сутки после окончания лечения во 2-й и 3-й группах ТРО составил 73,0 % и 30,1 % соответственно (р < 0,05). На 7-е и 14-е сутки после окончания применения РУ-185 во 2-й и 3-й группах объемы опухолей меньше в 3,5 и 1,4 раза (на 7-е сутки) и 2,3 и 1,3 раза (на 14-е сутки) соответственно, чем в контрольной группе (р < 0,05). В дозе 220 мг/кг показана полная регрессия опухолей LLC у 20 % животных. При росте B16-F10 продолжительность жизни во всех группах не различалась. Показаны межгрупповые различия динамики роста опухоли. Выраженные изменения обнаружены в 5-й группе (на 14-е сутки после окончания введения РУ-185 ТРО составил 48,7 %).

Заключение. Исследованная химическая субстанция дигидробромид-2-(3,4-дигидроксифенил)-9-диэтиламиноэтимидазо-[1,2-a] бензимидазола показала противоопухолевую эффективность в отношении сингенных опухолей: эпидермоидной карциномы легкого Льюиса и меланомы B16-F10 при внутрижелудочном введении, что обусловливает проведение дальнейших испытаний РУ-185 как потенциального препарата терапии злокачественных новообразований.

Ключевые слова: дигидробромид-2-(3,4-дигидроксифенил)-9-диэтиламиноэтимидазо-[1,2-a] бензимидазола, эпидермоидная карцинома легких Льюиса, меланома B16-F10, противоопухолевая эффективность, внутрижелудочное введение
INTRODUCTION

The search for targets for the treatment of malignant neoplasms, despite numerous developments in modern oncology, is still relevant [1–3]. The identified targets require the study of various means of influencing. Chemical substances, in particular benzimidazole derivatives, can be useful and effective for therapeutic purposes in practical oncology.

By its structure, benzimidazole is a heterocyclic compound in which benzene and imidazole rings are connected. The antitumor efficacy of imidazoles has long been known, some of which, for example, dacarbazine, temozolomide, zoledronic acid, mercaptopurine, nilotinib, tipifarnib, etc., are used in oncological practice in the treatment of various oncological diseases [4]. This antitumor effect of imidazoles is due to their ability to easily bind to protein molecules and destroy them, and in high concentrations directly inhibit the synthesis of the main components of the cell membrane [5].

The potential antitumor effect of benzimidazole is also due to the similarity of its structure with natural nucleotides, and therefore cell DNA is an important target for them. Thus, triazolobenzimidazole is able to inhibit checkpoint kinase 2, which plays an important role in the cell's response to DNA damage, and therefore has an antitumor effect [6]. The benzimidazole derivative 2-[(R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide can inhibit DNA repair by inhibiting poly (ADP-ribose) polymerase (PARP)-1 and –2 [7].

The effect of benzimidazole derivatives on the microtubule protein tubulin has been shown, in which its polymerization and depolymerization are disrupted [8]. The inhibitor of β-tubulin is benzimidazole-2-urea – it's cytotoxic effect against an extensive panel of tumor cells has been shown [9; 10]. The participation of some benzimidazole derivatives benzimidazole-4,7-diones in the activation of caspase-dependent apoptosis on the lung adenocarcinoma cell line was found [11].

The purpose of the study: to evaluate the effect of benzimidazole derivative dihydrobromide-2-(3,4-dihydroxyphenyl)-9-diethylaminoethylimidazo[1,2-a] benzimidazole (RU-185) on the growth of Lewis lung epidermoid carcinoma and melanoma B16-F10 with intragastric use.

MATERIALS AND METHODS

Mice of the C57Bl/6j female line weighing 20–22 grams were used for the experiment. The animals were obtained from the Andreevka vivarium of the FSBIC of biomedical technologies of FMABA Russia (Moscow region) with a veterinary certificate. The study was conducted according to the principles of humane treatment of animals in scientific research in accordance with the European Convention.

Table 1. Study design

| Groups/Number of animals | Supplement drug | Doses mg/kg | V, ml | Way of supplementation | Duration of supplementation |
|--------------------------|----------------|-------------|-------|------------------------|----------------------------|
| LLC                      |                |             |       |                        |                            |
| 1st 12 mice             | dihydrobromide-2-(3,4-dihydroxyphenyl)-9-diethylaminoethylimidazo[1,2-a] benzimidazole | 50          |       | I/g                    | 10 days                    |
| 2nd 12 mice             |                | 220         |       | I/g                    |                            |
| 3rd 12 mice             |                | 500         |       | I/g                    |                            |
| Control 12 mice         | Normal saline  | -           |       | I/g                    | 0.3 ml                     |
| B16-F10                 |                |             |       | I/g                    | 10 days                    |
| 4th 12 mice             | dihydrobromide-2-(3,4-dihydroxyphenyl)-9-diethylaminoethylimidazo[1,2-a] benzimidazole | 50          |       | I/g                    |                            |
| 5th 12 mice             |                | 220         |       | I/g                    |                            |
| 6th 12 mice             |                | 500         |       | I/g                    |                            |
| Control 12 mice         | Normal Saline  | -           |       | I/g                    |                            |

Note: LLC – Lewis lung epidermoid carcinoma, B16-F10 – melanoma, I/g – intragastric.
Syngenic tumors were used: Lewis epidermoid lung carcinoma (LLC) and melanoma B16-F10. The tumors were inoculated in mice subcutaneously in a standard way.

The design of the experiment is presented in Table 1. The investigated chemical substance dihydrobromide 2-(3,4-dihydroxyphenyl)-9-diethylaminoethylimidazo-[1,2-a] benzimidazole (RU-185) (RF patent No. 2391979) was dissolved in saline solution and administered intragastrically to animals using a nasogastric probe in a volume of 0.3 ml. The mode of administration was 10 days daily, 1 time per day.

The choice of doses to study the antitumor effect is due to the value of the semi-lethal toxicity of LD50, which was determined with a single intragastric administration to outbred mice (LD50 was 1860.4 mg/kg) [12]. For both tumors, depending on single doses of the substance for administration, groups were divided: 1st and 4th – 50 mg/kg, 2nd and 5th – 220 and 3rd and 6th – 500 mg/kg. The control groups, which consisted of animals with transplanted tumors B16-F10 and LLC, were intragastrically injected with saline solution in similar volumes and according to the same scheme. Both the surviving and fallen animals underwent necropsy within 2 hours after death.

The study of the antitumor activity of the substance was carried out in accordance with regulatory documents [13; 14], the following indicators were evaluated: tumor volume, increase in life expectancy (T/S, %), calculated as the ratio of the average life expectancy of animals subjected to therapy to control indicators, and the tumor growth inhibition index (TGI, %) was calculated.

The normality of the distribution of features was assessed using the Shapiro-Wilk and Kolmogorov-Smirnov criteria. Median and interquartile range were calculated for quantitative data. The statistical significance of the differences between the groups was assessed using the Mann-Whitney criterion, and in dynamics using the Wilcoxon criterion. The signifi-

| Table 2. The impact of PY-185 on LLC and B16-F10 growth dynamics |
|---------------------------------------------------------------|
| **Group number (Single dose, mg/kg)**                      | **Tumor volume (cm³), Me [25-75] (TGI, %)** |
|---------------------------------------------------------------|
| **Tumor volume (cm³), Me [25-75] (TGI, %)**                  |
| **The day after treatment termination**                      |
| **1**                                                        |
| **7**                                                        |
| **14**                                                       |
| **LLC**                                                      |
| 1st (50)                                                     |
| 94.3                                                        |
| 2.3 [1.9–2.7]                                                |
| 8.6 [7.8–9.2]                                                |
| 10.3 [9.9–10.9]                                              |
| 2nd (220)                                                    |
| 162.3                                                       |
| 0.4 [0.2–0.7]                                                |
| 2.1 [1.9–2.3]                                                |
| 4.5 [4.1–5.0]                                                |
| 55.0 – 80 % abdomen                                          |
| 0 (100) – 20 % abdomen                                        |
| 3rd (500)                                                    |
| 112.9                                                       |
| 1.1 [0.8–1.4]                                                |
| 5.2 [4.8–5.5]                                                |
| 7.4 [6.9–8.0]                                                |
| 28.6                                                         |
| Control                                                      |
| 0                                                           |
| 1.6 [1.1–2.1]                                               |
| 6.7 [6.3–7.1]                                               |
| 9.8 [9.3–10.2]                                              |
| **B16-F10 Melanoma**                                        |
| 4th (50)                                                     |
| 96.2                                                        |
| 0.4 [0.1–0.9]                                                |
| 2.7 [2.3–3.1]                                               |
| 5.9 [5.3–6.1]                                               |
| 5th (220)                                                    |
| 131.1                                                       |
| 0.4 [0.2–0.7]                                                |
| 2.6 [2.3–2.9]                                               |
| 2.4 [1.9–2.7]                                               |
| 48.7                                                         |
| 6th (500)                                                    |
| 103.1                                                       |
| 0.4 [0.1–0.9]                                                |
| 2.1 [1.8–2.4]                                               |
| 4.5 [3.9–4.9]                                               |
| 4.5                                                         |
| Control                                                      |
| 0.3 [0.1–0.7]                                               |
| 2.7 [2.1–3.4]                                               |
| 4.7 [3.9–5.1]                                               |

Note: 1 – the differences are significant relative to the control (p < 0.05); 2 – the differences are significant relative to the subgroups of the experimental group (p < 0.05).
The use of RU-185 in tumor-bearing animals with LLC caused a change in life expectancy and tumor size in experimental groups (Table 2). Thus, it was found that when a single dose of 220 mg/kg (group 2) was administered, an increase in life expectancy (T/S 162.3 %) was noted. In the group of animals administered a dose of 500 mg/kg (group 3), a tendency to increase the T/S index was shown, which has insignificant differences with the animals of the control group. In group 1, the life expectancy indicator was reduced in comparison with the control.

The study of the growth dynamics of the subcutaneous tumor node LLC with the use of RU-185 revealed differences in the study groups. On the 1st day after the end of treatment in the 2nd and 3rd groups, the tumor growth inhibition index indicated a decrease in the size of the primary focus and amounted to 73.0 % and 30.1 %, respectively (p < 0.05) (Table 2). On the 7th and 14th days after the end of the use of RU-185 in the 2nd and 3rd groups, tumor volumes were statistically significantly less by 3.5 and 1.4 times (on the 7th day) and 2.3 and 1.3 times (on the 14th day), respectively, than in the control group (p < 0.05). When applying a dose of 220 mg/kg, a complete regression of LLC tumors was shown in 20 % of animals, which was confirmed by the results of necropsy. At the same time, there was a tendency to tumor growth in group 1, but no statistically significant differences were found in comparison with the control group.

When analyzing the study results of the subcutaneous melanoma B16-F10 growth, we’ve shown that the life expectancy of all experimental groups didn’t differ from the control group (p > 0.05) (Table 2). The T/S index in tumor-bearing animals with melanoma B16-F10 when using RU-185 was 96.2, 131.1 and 103.1 %, respectively, in groups 4, 5 and 6.

Analysis of the dynamics of tumor growth in 16 showed intergroup differences. In the group with a single dose of RU-185 50 mg/kg, the administration of the substance did not affect the growth of the subcutaneous node, the tumor size indicators at all stages were similar to the control group. The most pronounced changes were shown in the group with a single dose of 220 mg/kg. So, on the 14th day after the end of the administration of RU-185, the TGI index was 48.7 %, which indicates a decrease in tumor size compared to the control group (by 2 times at p < 0.05).

**RESEARCH RESULTS AND DISCUSSION**

**CONCLUSION**

The studied chemical substance dihydrobromide-2-(3,4-dihydroxyphenyl)-9-diethylamino-ethylimidazo-[1,2-a] benzimidazole (RU-185) showed antitumor efficacy against syngenic transplantable tumors: Lewis lung epidermoid carcinoma and melanoma B16-F10. It was shown that with intragastric administration of the substance in a single dose of 220 mg/kg for 10 days, a significant decrease in the size of tumors was noted. In animals with melanoma B16-F10, a significant decrease in tumor volume occurs on the 14th day after the end of the administration of the substance. Unlike melanoma, in animals with epidermoid lung carcinoma at a dose of 220 mg/kg, RU-185 has a pronounced inhibition of the growth of the subcutaneous tumor node already on the first day after the end of the use of the substance.

We explain the differences in the effectiveness of the substance under study by the peculiarities of metabolic phenotypes of tumors. Metabolic phenotypes of melanoma demonstrate dynamism between glycolysis and oxidative phosphorylation, which gives an advantage in the survival of tumor cells and in the formation of chemoresistance [15; 16]. Moreover, simultaneous activation of both oxidative phosphorylation and glycolysis (metabolic symbiosis) is vital for the progression of melanoma [15; 16]. At the same time, the metabolism of lung cancer cells is characterized by the activation of glucose oxidation enzymes, which indicates it’s glycolytic phenotype [17]. Along with the activation of glycolysis for lung cancer, an increase in the intensity of other glucose-related processes, such as gluconeogenesis, the tricarboxylic acid cycle, has been shown [17].

Thus, the revealed antitumor efficacy of dihydrobromide-2-(3,4-dihydroxyphenyl)-9-diethylaminooethylimidazo-[1,2-a] benzimidazole determines further testing of RU-185 as a potential drug for the treatment of malignant neoplasms. However, further studies are needed to identify the mechanism of it’s antitumor action.
Reference

1. Kit O I, Shaposhnikov AV, Zlatnik E Yu, Nikipelova E A, Novikova I A. Local cellular immunity in adenocarcinoma and colon polyps. Siberian Medical Review. 2012;(4(76)):11–16. (In Russ.).
2. Kit OI, Frantsiyants EM, Nikipelova EA, Komarova EF, Kozlova LS, Tavaryan IS, et al. Changes in markers of proliferation, neoangiogenesis and plasminogen activation system in rectal cancer tissue. Experimental and Clinical Gastroenterology. 2015;(2(114)):40–45. (In Russ.).
3. Shatova OP, Komarova EF, Ishenko RV, Komarova EJu. Peculiarities of glucose metabolism in tumor tissue and blood serum in breast cancer. Modern problems of science and education. 2020;(2):117. (In Russ.). https://doi.org/10.17513/spno.29634
4. Ali I, Lone MN, Aboul-Enein HY. Imidazoles as potential anticancer agents. Medchemcomm. 2017 Sep 1;8(9):1742–1773. https://doi.org/10.1039/c7md00067g
5. Shalini K, Sharma PK, Kumar N. Imidazole and its biological activities: A review. Chem. Sin. 2010;1:36-47.
6. Silva-Santisteban MC, Westwood IM, Boxall K, Brown N, Peacock S, McAndrew C, et al. Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2. PLoS One. 2013;8(6):e65689. https://doi.org/10.1371/journal.pone.0065689
7. Penning TD, Zhu G-D, Gandhi VB, Gong J, Liu X, Shi Y, et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009 Jan 22;52(2):514–523. https://doi.org/10.1021/jm801171j
8. Torres FC, García-Rubiño ME, Lozano-López C, Kawano DF, Eifler-Lima VL, von Poser GL, et al. Imidazoles and benimidazoles as tubulin-modulators for anti-cancer therapy. Curr Med Chem. 2015;22(11):1312–1323. https://doi.org/10.2174/0929867322666150114164032
9. Wang W, Kong D, Cheng H, Tan L, Zhang Z, Zhuang X, et al. New benzimidazole-2-urea derivates as tubulin inhibitors. Bioorg Med Chem Lett. 2014 Sep 1;24(17):4250–4253. https://doi.org/10.1016/j.bmcl.2014.07.035
10. Khattab M. Theoretical study of the geometric and electronic characterization of carbendazim-based drug (Nocodazole). Heliyon. 2020 Jun;6(6):e04055. https://doi.org/10.1016/j.heliyon.2020.e04055
11. Blaszczyk-Świątkiewicz K, Olszewska P, Mikiciuk-Olasik E. Biological approach of anticancer activity of new benimidazole derivatives. Pharmacol Rep. 2014 Feb;66(1):100–106. https://doi.org/10.1016/j.pharep.2014.01.001
12. GOST 32296-2013. Test methods for the effects of chemical products on the human body. Moscow, 2014. (In Russ.).
13. GOST 33044-2014. Principles of good laboratory practice. Moscow, 2015. (In Russ.).
14. Guidelines for conducting preclinical studies of medicines. Ed. by A. N. Mironov. Moscow: Vulture and K, 2013, 944 p.
15. Kumar PR, Moore JA, Bowles KM, Rushworth SA, Moncrieff MD. Mitochondrial oxidative phosphorylation in cutaneous melanoma. Modern problems of science and education. 2020;(2):117. (In Russ.). https://doi.org/10.17513/spno.29634
16. Neagu M. Metabolic Traits in Cutaneous Melanoma. Front Oncol. 2015;(2(114)):40–45. (In Russ.).
17. Vanhove K, Graulus G-J, Mesotten L, Thomeer M, Derveaux E, Noben J-P, et al. The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism. Front Oncol. 2019 Nov 15;9:1215. https://doi.org/10.3389/fonc.2019.01215
18. Guidelines for conducting preclinical studies of medicines. Ed. by A. N. Mironov. Moscow: Vulture and K, 2013, 944 p.
19. Shalini K, Sharma PK, Kumar N. Imidazole and its biological activities: A review. Chem. Sin. 2010;1:36-47.
20. GOST 33044-2014. Principles of good laboratory practice. Moscow, 2015. (In Russ.).
21. GOST 32296-2013. Test methods for the effects of chemical products on the human body. Moscow, 2014. (In Russ.).
22. GOST 33044-2014. Principles of good laboratory practice. Moscow, 2015. (In Russ.).
23. Guidelines for conducting preclinical studies of medicines. Ed. by A. N. Mironov. Moscow: Vulture and K, 2013, 944 p.
24. Kumar PR, Moore JA, Bowles KM, Rushworth SA, Moncrieff MD. Mitochondrial oxidative phosphorylation in cutaneous melanoma. Modern problems of science and education. 2020;(2):117. (In Russ.). https://doi.org/10.17513/spno.29634
25. Neagu M. Metabolic Traits in Cutaneous Melanoma. Front Oncol. 2015;(2(114)):40–45. (In Russ.).
26. Shalini K, Sharma PK, Kumar N. Imidazole and its biological activities: A review. Chem. Sin. 2010;1:36-47.
27. GOST 32296-2013. Test methods for the effects of chemical products on the human body. Moscow, 2014. (In Russ.).
28. GOST 33044-2014. Principles of good laboratory practice. Moscow, 2015. (In Russ.).
29. Guidelines for conducting preclinical studies of medicines. Ed. by A. N. Mironov. Moscow: Vulture and K, 2013, 944 p.
30. Kumar PR, Moore JA, Bowles KM, Rushworth SA, Moncrieff MD. Mitochondrial oxidative phosphorylation in cutaneous melanoma. Modern problems of science and education. 2020;(2):117. (In Russ.). https://doi.org/10.17513/spno.29634
31. Neagu M. Metabolic Traits in Cutaneous Melanoma. Front Oncol. 2015;(2(114)):40–45. (In Russ.).
Luiza Z. Kurbanova – junior research fellow, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation. ORCID: https://orcid.org/0000-0003-3436-1325, SPIN: 9060-4853, AuthorID: 1020533

Mariya V. Mindar – junior research fellow, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation. ORCID: https://orcid.org/0000-0001-8734-9210, SPIN: 5148-0830, AuthorID: 1032029

Ekaterina V. Zaikina – junior research fellow, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation. ORCID: https://orcid.org/0000-0003-0088-2990, SPIN: 4000-4369, AuthorID: 1045258

Anastasiya V. Galina – junior research fellow, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation. ORCID: https://orcid.org/0000-0001-7823-3865, SPIN: 9171-4476, AuthorID: 1071933

**Contribution of the authors:**

Komarova E. F. – research concept and design, text writing, scientific editing, material processing, data analysis and interpretation, article preparation;

Morkovnik A. S. – substance synthesis, text writing, scientific editing, material processing, data analysis and interpretation;

Zhukovskaya O. N. – substance synthesis, data analysis and interpretation;

Verenikina E. V. – research concept and design, text writing, scientific editing;

Shevchenko N. A. – statistical processing of the results, preparation of the article;

Khodakova D. V. – working with animals, material processing;

Kurbanova L. Z. – working with animals, working with literature;

Mindar M. V. – working with animals, material processing;

Zaikina E. V. – working with literature, preparing an article;

Galina A. V – working with animals, technical editing.